

## QIBA US Coordinating Committee (CC) Call

Friday, December 8, 2017 at 11 AM CT

### Call Summary

#### In attendance

Brian Garra, MD (Co-Chair)	Paul Carson, PhD	Nancy Obuchowski, PhD	RSNA Joe Koudelik
Timothy Hall, PhD (Co-Chair)	Todd Erpelding, PhD	Kevin O'Donnell, MASc	Susan Weinmann
S. Kaisar Alam, PhD	Edward Jackson, PhD	Anthony Samir, MD, MPH	
Michalakis Averkiou, PhD	Oliver Kripfgans, PhD	Theresa Tuthill, PhD	
Richard Barr, MD, PhD	Michael MacDonald, PhD	Keith Wear, PhD	

*Moderator: Dr. Hall*

#### Approval of Call Summary

- The notes from September 29, 2017 were approved as amended

#### US SWS Biomarker Committee Update

- Dr. Guimaraes to reach out to Drs. Palmeri and Ehman to learn more about the collaborative process and liaison activities of two different modalities as experienced by MRE and US-SWS BCs
- Drs. Garra and Obuchowski met offline to discuss the edited Claims section in the Profile
- Dr. Obuchowski's conformance document to be integrated into the Profile
- Questions in the margin regarding hyperlinks to be addressed
- Dr. Garra to send latest Profile draft to Mr. O'Donnell for review
- Profile draft with new Claims to be distributed to US-SWS BC members when ready
- Assignment of subject matter experts (SMEs) to each Profile section suggested to ease the review burden
- Mr. O'Donnell provided an overview on the public comment process; the following information can be found on the QIBA Wiki:
  - Prior to public comment, there will be a review process as described at:  
[http://qibawiki.rsna.org/index.php/Review\\_Process](http://qibawiki.rsna.org/index.php/Review_Process)
  - Profile stages criteria can be found at:  
[http://qibawiki.rsna.org/index.php/QIBA\\_Profile\\_Stages](http://qibawiki.rsna.org/index.php/QIBA_Profile_Stages)
    - US-SWS BC to conduct an in-depth review of the Profile and vote to release it for public comment
    - US Coordinating Cmte to conduct a high-level review of the Profile and vote to release it for public comment
    - The public comment process is described at:  
[http://qibawiki.rsna.org/index.php/Public\\_Comment\\_Process](http://qibawiki.rsna.org/index.php/Public_Comment_Process)
      - A four-week public comment period was suggested
- Dr. Palmeri forwarded a draft manuscript of phantom studies; it is almost ready to be submitted for publication
- Dr. Garra discussed his and Dr. Samir's Round-6 collaborative project
  - As stated in the IRB proposal, a total of 30 subjects is needed at each site for this project
  - To date, 21 or 22 subjects have been scanned

- Two distinct protocol performance deviations introduced to assess real-world consequences of not adhering to the protocol
  - Patient movement / breathing
  - Transducer movement
  - Fewer than 10 acquisitions
- Final data analysis expected by end of March 2018
- A large amount of technical data was examined and issues in vendor software were identified
- A fair amount of variation in one of the systems was detected
- IRB approval for additional subjects was received
- A recent VA scanner software upgrade (code) install did not work; hope to have systems operational by 1Q2018
- There was discussion on progressing with system comparisons during QIBA Working Meeting Breakout Session at the RSNA Annual Meeting:
  - Some difference among systems was detected, but there was overall agreement
  - Discussion ensued on incentives for manufacturers to make modifications to further improve agreement across equipment, subjects, software, etc.
    - One phantom manufacturer will make a set of phantoms that will be calibrated and with publicly-available software codes, which will establish a basis for manufacturers to replicate
    - Duke and Mayo are willing assist with calibrating the CIRS phantom
    - Once calibration is completed, an equipment vendor would be able to claim that they have QIBA-conforming equipment, which will add market value
  - Mr. O'Donnell recommended touching base with a MITA representative whose area is scanning equipment
  - Public comment is a good opportunity to reach stakeholders outside of QIBA and target them to review and comment on the Profile
  - Bracco rep to contact Dr. Garra regarding FDA approval efforts for Viewbox

#### **US VBF Biomarker Committee Update**

- Seven of nine sites have completed phantom scanning on three commercial systems from three different vendors
- Two additional systems yet to be tested
- Limitations discovered during phantom testing may be overcome
- Statistical analysis (with which assistance from Dr. Obuchowski will be needed) will be the next task
  - Dr. Obuchowski to provide guidance on how to approach data in a way that is most compatible with QIBA
- Adequate reference standards were discussed during the breakout session at the QIBA Working Meeting
  - Dialysis as well as color flow measurements

### **US CEUS Biomarker Committee Update**

- Dr. Erpelding was welcomed as the third co-chair of this biomarker committee
- Data have continued to be collected since the Q3 US CC t-con
- Progress is being made on the literature review through the literature database; it is about 70% completed
- Drs. Barr and Carson conducted noontime MTE sessions at the QIBA Kiosk that were very well-attended and produced useful discussion
- Five people attended the breakout session at the QIBA Working Meeting

---

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, **if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible.** Call participants are welcome to contact RSNA staff at [QIBA@RSNA.org](mailto:QIBA@RSNA.org) if their attendance is not reflected on the call summaries.